Meeting
2020 Gastrointestinal Cancers Symposium
Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience.
Authors
Mashiro Okunaka
Department of Pharmacy, National Cancer Center Hospital East, Japan, Kashiwa, Japan
Mashiro Okunaka , Daisuke Kotani , Ken Demachi , Akihito Kawazoe , Takayuki Yoshino , Kohei Shitara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 322)
Abstract #
322
Poster Bd #
B19
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).
First Author: Kenro Hirata
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX trial (JACCRO GC-09).
First Author: Takahisa Suzuki
First Author: Sylvie Lorenzen
Poster
2021 Gastrointestinal Cancers Symposium
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).
First Author: Yasuyuki Kawamoto